Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

CONTEXT: Hepatitis C virus (HCV) infection is a major cause of liver-morbidity and mortality among patients with thalassemia. Peginterferon plus ribavirin is currently the recommended therapy for hepatitis C infection in patients do not have thalassemia, but using ribavirin in patients with thalasse...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hepat Mon
Auteurs principaux: Aminizadeh, Ehsan, Alavian, Seyed Moayyed, Akbari Sari, Ali, Ebrahimi Daryani, Nasser, Behnava, Bita
Format: Artigo
Langue:Inglês
Publié: Kowsar 2016
Sujets:
Review Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876663/
https://ncbi.nlm.nih.gov/pubmed/27226796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/hepatmon.28537
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires